Related references
Note: Only part of the references are listed.Direct evidence for cancer-cell-autonomous extracellular protein catabolism in pancreatic tumors
Shawn M. Davidson et al.
NATURE MEDICINE (2017)
HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Manish A. Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer
Stephen J. Bagley et al.
LUNG CANCER (2017)
Evaluation of dosing strategy for pembrolizumab for oncology indications
Tomoko Freshwater et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Pharmacokinetics of Monoclonal Antibodies
Josiah T. Ryman et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors
X. Zhao et al.
ANNALS OF ONCOLOGY (2017)
Clinical Pharmacokinetics and Pharmacodynamics of Atezolizumab in Metastatic Urothelial Carcinoma
M. Stroh et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
US FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab
Maitreyee Hazarika et al.
CLINICAL CANCER RESEARCH (2017)
PD-1 and PD-L1 antibodies in cancer: current status and future directions
Arjun Vasant Balar et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis
C. Liu et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors
M. Ahamadi et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors
G. Bajaj et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
P. F. Ferrucci et al.
ANNALS OF ONCOLOGY (2016)
Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors
Amit Garg et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
Arnoud J. Templeton et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
The Combination of Exposure-Response and Case-Control Analyses in Regulatory Decision Making
Jun Yang et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose
R. J. Keizer et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2013)
A Fast Method for Testing Covariates in Population PK/PD Models
Akash Khandelwal et al.
AAPS JOURNAL (2011)
Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis
A.A. Fasanmade et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2011)
Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL-12/23p40, in Patients With Moderate to Severe Plaque Psoriasis
Yaowei Zhu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Clinical pharmacokinetics of bevacizumab in patients with solid tumors
Jian-Feng Lu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
PsN-Toolkit - A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM
L Lindbom et al.
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE (2005)
Perls-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming
L Lindbom et al.
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE (2004)
Share Paper
